Characteristics of studies (<i>n</i> = 22). حسب Kuo-Chuan Hung (8587392)

"…Trial sequential analysis (TSA) was conducted to validate the reliability.</p><p>Results</p><p>A meta-analysis of 22 RCTs (n = 3,463) showed that ketamine/esketamine significantly decreased PPD risk at 1- (risk ratio [RR], 0.41; 95% confidence interval [CI], 0.3–0.57) and 4–6-week (RR, 0.47; 95%CI, 0.35–0.63) follow-ups. …"

Table_1_Predicting cancer-related mycobiome aspects in gastrointestinal cancers: a systematic review.docx حسب György Szklenarik (20296893)

"…Observing the interindividual variability, we found that the Ascomycota/Basidiomycota (A/B) ratio from healthy to cancer state decreased in n = 2, increased in n = 1 cases, and did not change significantly in n = 2 studies. …"

Image 1_Distinct brain and neurocognitive transformations after bariatric surgery: a pilot study.jpeg حسب Bhaswati Roy (2802559)

"…</p>Results<p>At baseline, obese patients had significant brain tissue changes seen in MRI and decreased cognitive scores compared to controls (MoCA 26 vs 28, P = 0.017). …"

Table 1_Sex disparities in the risk of intracranial aneurysm rupture: a case–control study.docx حسب Dong Shen (485693)

"…Compared with males, females had a higher risk of ruptured IA [odds ratio, 1.72 (95% confidence interval, 1.38–2.14)]. …"

Table 1_Singing for memory: neural and cognitive effects of a choral intervention in older adults.docx حسب Miriam Napadow (17538380)

"…The study included examinations at three time points: T1, T2, and T3. A control period (T1-T2) was followed by the intervention period (T2-T3), each lasting approximately 11 months. …"

Datasheet1_Causal relationship between immunophenotypes and mitral valve prolapse: a bidirectional Mendelian randomization study.pdf حسب Yue Wang (65477)

"…Background<p>Emerging evidence indicates a significant link between various immune cell types and the development of heart valve disorders. …"

Table1_Causal relationship between immunophenotypes and mitral valve prolapse: a bidirectional Mendelian randomization study.xlsx حسب Yue Wang (65477)

"…Background<p>Emerging evidence indicates a significant link between various immune cell types and the development of heart valve disorders. …"

Data Sheet 1_A Delphi-based framework for optimizing nurse staffing in Chinese hospitals.pdf حسب Waner Wang (17773704)

Fine mapping of the <i>PSV1</i> locus implicates the mitotic cell cycle regulator <i>DUO3.</i> حسب Matthew T. Parker (10217926)

"…Sperm nuclei that inherit the Db-1 haplotype of <i>PSV1</i> have significantly increased expression of <i>UBC20</i> and decreased expression of <i>CYCB1;2</i>, compared to sister nuclei that inherit the Col-0 haplotype. …"

Primers for qPCR. حسب Kaitao Zhao (3617825)

"…Results revealed the MRE11–RAD50–NBS1 (MRN) complex as a potential factor. Transiently or stably knockdown of MRE11, RAD50 or NBS1 in hepatocytes before HBV infection significantly decreased viral markers, including cccDNA, while reconstitution reversed the effect. …"

Antibodies used for western blotting. حسب Kaitao Zhao (3617825)

"…Results revealed the MRE11–RAD50–NBS1 (MRN) complex as a potential factor. Transiently or stably knockdown of MRE11, RAD50 or NBS1 in hepatocytes before HBV infection significantly decreased viral markers, including cccDNA, while reconstitution reversed the effect. …"

Target sequences of siRNAs. حسب Kaitao Zhao (3617825)

"…Results revealed the MRE11–RAD50–NBS1 (MRN) complex as a potential factor. Transiently or stably knockdown of MRE11, RAD50 or NBS1 in hepatocytes before HBV infection significantly decreased viral markers, including cccDNA, while reconstitution reversed the effect. …"

Plasmids information. حسب Kaitao Zhao (3617825)

"…Results revealed the MRE11–RAD50–NBS1 (MRN) complex as a potential factor. Transiently or stably knockdown of MRE11, RAD50 or NBS1 in hepatocytes before HBV infection significantly decreased viral markers, including cccDNA, while reconstitution reversed the effect. …"

Raw data. حسب Kaitao Zhao (3617825)

"…Results revealed the MRE11–RAD50–NBS1 (MRN) complex as a potential factor. Transiently or stably knockdown of MRE11, RAD50 or NBS1 in hepatocytes before HBV infection significantly decreased viral markers, including cccDNA, while reconstitution reversed the effect. …"

<i>T</i>₂ spectra distribution of samples. حسب Yanxu Liang (22227024)

"…The study shows that: (1) With the increase of unloading amplitude, there is an increase in the number of nascent cracks and a tendency to expand, which is caused by shear extension cracks; with the increase of unloading amplitude, there is a tendency for the microporosity to shift to the mesoporosity, and the mesoporosity has a tendency to shift to the macroporosity, and there is a decrease in the number of micropores as a whole, which indicates that there is almost no new pore sprouting. (2) When the unloading amplitude is less than 20MPa, with the increase of the unloading amplitude, the pore ratio and expansion rate of the specimen increase slowly; when the unloading amplitude is more than 20MPa, with the increase of the unloading amplitude, the pore ratio and expansion rate of the specimen have a significant tendency to increase. (3) With the increase of unloading amplitude, the shale shear strength limit value decreases more slowly, the modulus of elasticity and shear strength also show a similar pattern of change, and the same way to derive the rock Poisson’s ratio does not change much.…"

Image 4_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... حسب Chao Song (379006)

"…</p>Results<p>Three RCTs (IMpower150, jRCT2080224500, and ORIENT-31) comprising a total of 1529 patients were analyzed. The PIBC regimen significantly improved PFS (hazard ratio [HR]: 0.76 [0.66, 0.87], P < 0.0001), objective response rate (risk ratio [RR]: 1.36 [1.22, 1.51], P < 0.00001), and disease control rate (RR: 1.06 [1.00, 1.12], P = 0.04). …"

Table 3_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... حسب Chao Song (379006)

"…</p>Results<p>Three RCTs (IMpower150, jRCT2080224500, and ORIENT-31) comprising a total of 1529 patients were analyzed. The PIBC regimen significantly improved PFS (hazard ratio [HR]: 0.76 [0.66, 0.87], P < 0.0001), objective response rate (risk ratio [RR]: 1.36 [1.22, 1.51], P < 0.00001), and disease control rate (RR: 1.06 [1.00, 1.12], P = 0.04). …"

Image 2_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... حسب Chao Song (379006)

"…</p>Results<p>Three RCTs (IMpower150, jRCT2080224500, and ORIENT-31) comprising a total of 1529 patients were analyzed. The PIBC regimen significantly improved PFS (hazard ratio [HR]: 0.76 [0.66, 0.87], P < 0.0001), objective response rate (risk ratio [RR]: 1.36 [1.22, 1.51], P < 0.00001), and disease control rate (RR: 1.06 [1.00, 1.12], P = 0.04). …"

Table 7_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... حسب Chao Song (379006)

"…</p>Results<p>Three RCTs (IMpower150, jRCT2080224500, and ORIENT-31) comprising a total of 1529 patients were analyzed. The PIBC regimen significantly improved PFS (hazard ratio [HR]: 0.76 [0.66, 0.87], P < 0.0001), objective response rate (risk ratio [RR]: 1.36 [1.22, 1.51], P < 0.00001), and disease control rate (RR: 1.06 [1.00, 1.12], P = 0.04). …"

Table 8_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... حسب Chao Song (379006)

"…</p>Results<p>Three RCTs (IMpower150, jRCT2080224500, and ORIENT-31) comprising a total of 1529 patients were analyzed. The PIBC regimen significantly improved PFS (hazard ratio [HR]: 0.76 [0.66, 0.87], P < 0.0001), objective response rate (risk ratio [RR]: 1.36 [1.22, 1.51], P < 0.00001), and disease control rate (RR: 1.06 [1.00, 1.12], P = 0.04). …"